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Abstract 	
Recent epidemiological evidences indicate that arsenic exposure increases risk of 
atherosclerosis, cardio vascular diseases (CVD) such as hypertension, atherosclerosis, 
coronary artery disease (CAD) and microangiopathies in addition to the serious global 
health concern related to its carcinogenic effects. In experiments on animals, acute and 
chronic exposure to arsenic directly correlates cardiac tachyarrhythmia, and 
atherogenesis in a concentration and duration dependent manner. Moreover, the other 
effects of long-term arsenic exposure include induction of non-insulin dependent 
diabetes by mechanisms yet to be understood. On the other hand, there are 
controversial issues, gaps in knowledge, and future research priorities of accelerated 
incidences of CVD and mortalities in patients with HIV who are under long-term anti-
retroviral therapy (ART). Although, both HIV infection itself and various components of 
ART initiate significant pathological alterations in the myocardium and the vasculature, 
simultaneous environmental exposure to arsenic which is more convincingly being 
recognized as a facilitator of HIV viral cycling in the infected immune cells, may 
contribute an additional layer of adversity in these patients. A high degree of suspicion 
and early screening may allow appropriate interventional guidelines to improve the 
quality of lives of those affected. In this mini-review which have been fortified with our 
own preliminary data, we will discuss some of the key current understating of chronic 
arsenic exposure, and its possible impact on the accelerated HIV/ART induced CVD. 
The review will conclude with notes on recent developments in mathematical modeling 
in this field that probabilistically forecast incidence prevalence as functions of aging and 
life style parameters, most of which vary with time themselves; this interdisciplinary 
approach provides a complementary kernel to conventional biology. 	
 
 
ABBREVIATIONS: As2O3, arsenic trioxide; AsV, arsenate; AsIII, arsenite; CAD, 
coronary artery disease; CVD, cardiovascular disease; EC, endothelial cell; NO, nitric 
oxide; NOS, nitric oxide synthase; eNOS, endothelial nitric oxide synthase; ROS, 
reactive oxygen species. 
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Introduction	
The World of Arsenic 
The knowledge of medicinal and 
homicidal use of arsenic can be 
traced back to the early days of 
human civilization. The poisonous 
and carcinogenic properties of 
arsenic compounds, or 
“Arsenicals”, have been known for 
more than 2000 years [2, 3]. In the 
west, much of the current 
awareness can be traced back to 
the 1944 comedy movie Arsenic and Old Lace 
(http://www.imdb.com/title/tt0036613/). Emperors, 
kings, arctic explorers, heirs and commoners have 
been treated with arsenicals for both legitimate and 
homicidal purposes. A popular myth suggests that in 
55 AD, the infamous 
Roman emperor Nero 
poisoned his stepbrother 
Britannicus with arsenic 
before his 14th birthday. 
Conversely, Hippocrates 
used arsenicals to treat 
ulcers. 	
In the course of time, Arsenicals made their place in 
medicine for treating sleeping 
sickness, syphilis, tuberculosis and certain skin diseases. 
In the early 1800s, Arsenic exposure was linked to cancer 
leading to a progressive diminution in its medicinal use.   
Arsenical have widespread use in embalming during and 
after the American Civil War, and today, Arsenic leaching 
from old cemeteries is a known groundwater pollutant in 
the Unites States. Arsenic has been used widely in the 
United States as a wood preservative until the year 2004 
[4].  Eventually, as wood comes into contact with soil and 
water, it releases Arsenic to the environment.  This is a 
major source of Arsenic in the environment, in particular in 
children playgrounds. In addition, Arsenic plays an 
important role in the semiconductor industry in the form of 
gallium arsenide, a compound used in a wide range of 
electronic devices [5].	
1. In the 1800s, Fowler’s 
solution, a 1% potassium 
arsenite solution, was used 
as a general tonic for treating 
leukemia, psoriasis, and 
asthma. Fowler’s solution was 
not withdrawn from the US 
market until the 1950s.	
2. The arsenic-containing drug 
melarsoprol is still the drug 
of choice for treating African 
trypanosomiasis.	
	
AIR: Arsenic in air range from 0.02 to 4ng/m3) in remote 
and rural areas, to (3 to ~ 200ng/m3) in urban areas, 
higher concentrations (more than 1000 ng/ m3) can be 
found near industrial, in some countries. 
 
WATER: Open ocean seawater are typically low (1–2 
µg/l) whereas surface waters may be 1000 times higher 
(up to 5000 µg/l). Arsenic levels in groundwater are 
typically as low as in open ocean water (about 1–2 µg/l), 
except in areas with volcanic rock and sulphide mineral 
deposits where arsenic levels can range up to 3000 µg/l. 
 
In sediment: Arsenic concentrations range from 5 to 
3000 mg/kg. The higher levels are found in areas 
contaminated by mining and smelting. In soil, 
concentrations range from 1 to 40 mg/kg, usually 
averaging around 5 mg/kg. 
 
Marine Biome: Marine organisms normally contain 
arsenic residues ranging from < 1 to more than 
100mg/kg, predominantly as organic arsenic species 
such as arsenosugars (macroalgae) and arsenobetaine 
(invertebrates and fish).  
 
Terrestrial plants: Plants may accumulate arsenic by 
root uptake from the soil or by adsorption of airborne 
arsenic deposited on the leaves. Arsenic levels are higher 
in biota collected near anthropogenic sources or in areas 
with geothermal activity.  
 
Sources of Occupational Exposure to Arsenic 
1.  Semi-conductors industry, notably of 
fast chips based on gallium arsenide often 
involving the toxic gas ARSINE, AsH3. 
2.  Glass manufacturing. 
3.  Mining operations and purification of 
metal ores and metals. Specifically, 
sulfide base ore processing ( iron pyrite, 
lead sulfide) 
4.  Manufacturing of certain drugs, Cattle 
and poultry food additives (some anti-
cancer drugs, e.g. Roxarsone). 
5.  Manufacturing and use of pesticides 
and insecticides which contain Arsenic. 
6.  Wood Treatment 
7.  Rat and animal poisons. 
8.  Old paints 
N.B. Although in most countries the use of Arsenic and its 
compounds for Applications 5, 6, 7 and 8 has been banned or 
discontinued, there are still many products that contain Arsenic 
which were manufactured before the ban took effect. This includes 
treated wood in children playgrounds and old containers of rat 
	
An ACUTE FATAL DOSE of Arsenic is in the 
range of 2-20 mg/kg body weight/day. Thus, a 
relatively healthy person with a body weight of 
75 kg may die if he ingests about 145 mg to 
1.45gm of Arsenic Trioxide (most commonly 
available arsenic compound). Considering the 
high density of the oxide, less than 1/8 of a tea 
spoon can be fatal. Smaller amounts may be 
fatal for exposed unhealthy people, elderly or 
children. The symptoms of poisoning by SMALL 
amounts of Arsenic are indistinguishable from 
symptoms of other illness.  
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 Most Arsenic in the terrestrial environment is found in rocks and soils. Arsenic in 
surface and ground water is mostly a mixture of arsenite and arsenate. Arsenic is widely 
distributed in food; particularly high levels are found in 
seafood [6]. The major man-made sources of Arsenic 
include coal combustion, nonferrous metal smelting, and 
the burning of agricultural wastes. Arsenic compounds 
have been widely used as herbicides, fungicides, wood 
preservatives, desiccants, cattle and sheep dips, and as 
coloring agents. Arsenic continues to be widely used in 
agriculture, in glass and ceramics, as a metal alloy, and in 
semiconductors and other electronic devices. In the past, 
Arsenic containing rodenticides and ant poisons were 
responsible for many exposures. Suicidal and homicidal 
poisonings continue to be reported. Bacteria within soils 
and sediments can transform arsenate to arsenite, which 
can be converted into methylarsenic acid.  Also within the 
soils and sediments, bacteria can transform 
methylarsenic acid into dimethylarsinic acid.  All these 
arsenic compounds are then sublimated through rain and thereby percolate into drinking 
water. Molds can convert methylarsenic acid into trimethylarsine, which can then also 
be available within water.  In addition, molds and bacteria can convert dimethylarsinic 
acid into both trimethylarsine and dimethylarsine in water.  Once in water, 
trimethylarsine and dimethylarsine can volatilize into the atmosphere.  Therefore, 
different forms of Arsenic can be found in the soil, sediments, water, atmosphere and 
the food chain. (Reviewed in:[7]).	
Non-occupational human exposure to arsenic in the environment is primarily through the 
ingestion of food and water [8, 9]. Arsenic has been detected in groundwater in several 
countries of the world, with concentration levels exceeding the WHO drinking water 
guideline value of 10 μg/L (WHO) as well as the national regulatory standards (e.g. 50 
μg/L in India and Bangladesh)[10, 11]. Arsenic in groundwater is often associated with 
geologic sources. Today, arsenic contamination of drinking water is a major worldwide 
public health problem. A very large number of people in India and in different parts of 
the world (countries like Bangladesh, Chile, Taiwan, Mexico, Thailand, Germany and 
parts of China) are being highly affected due to the intake of arsenic contaminated 
ground water [8, 10-12]. A significant fraction of the population living in the Indian 
districts of West Bengal (e.g. Maldaha, Murshidabad, Nadia, Bardhaman, Hooghly, 24-
Parganas, and Kolkata) are also under heavy environmental exposure to arsenic and 
suffer from the effects of chronic arsenic toxicities initiating an alarmingly high incidence 
of skin, bladder and lung and also ‘Blackfoot’ disease (arsenic induced oxidative stress, 
microvascular damage and gangrene of foot)[13-
16].	
The daily intake of total arsenic from food and 
beverages is generally between 20 and 300 µg/day. 
Foodstuffs such as meat, poultry, dairy products and 
Sources of Exposure to Arsenic in Daily Life.	
1. Most drinking water contains small amounts 
of Arsenic. Natural water leaches small 
amounts of Arsenic from rocks and sand. 
Some industrial operations sometimes 
contaminate water with Arsenic. 
2. Arsenic was found in items such as wine, 
juice, syrup, glues and pigments. 
3. Arsenic is found in many foods both as 
organic compounds such as methyl arsines, 
and as inorganic arsenates and arsinates. 
The organic compounds are less toxic than 
the inorganic compounds. 
4. Inorganic arsenic compounds were found in 
apple juice, orange and grapefruit juice, in 
vinegars and salad dressings, in milk and 
dairy products, beef, pork, poultry and in 
cereal. 
5. Arsenic is found in most unshelled rice but 
also in shelled rice and in its products.	
Roxarsone is an organoarsenic compound that is 
widely used in the poultry, pork, and cattle industry as 
a food additive to increase weight gain and 
improve feed efficiency. The drug was also approved in 
the United States for use in pigs. Roxarsone is 
marketed** as 3-Nitro by Zoetis, a former subsidiary 
of Pfizer. In 2006, approximately one million 
kilograms of Roxarsone were produced in the U.S. 
**Use of Roxarsone was discontinued in the US since 2011 
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cereals have higher levels of inorganic Arsenic [17]. Pulmonary exposure may 
contribute up to approximately 10 µg/day in a smoker and about 1 µg/day in a non-
smoker, and more in polluted areas. The concentration of metabolites of inorganic 
arsenic in urine ranges from 5 to 20 µg of Arsenic/liter, but may even exceed 1000 
µg/liter. In workplaces with up-to-date occupational hygiene practice, exposure generally 
does not exceed 10 µg/m3 (8-h time-weighted average.  Concentrations as low as 0.5 
ppm Arsenic may trigger the initial symptoms of exposure [18].  
The symptoms of small-to-moderate exposure to arsenic may appear immediately or 
only after several hours include headaches, vertigo and nausea. Subsequently, 
problems related to oxygen transfer in the body due to interferences with the 
hemoglobin, along with possible impairment of renal functions.  
Exposure to small doses of Arsenic 
compounds over a long period of time can 
result in lung, skin or liver cancer, or cancer 
of the lymphatic system [19], including 
damage to organs, such as the esophagus, 
as also   confusion and disorientation. 
Arsenic mainly enters via drinking water or 
food that has been eaten but it can also 
penetrate into the body through the skin or 
the 
lung
s 
[20]. 
Most Arsenic compounds are soluble in water 
to some extent and thus are easily transported 
in the blood stream and assimilated by the 
body. The water solubility also helps remove 
some of the Arsenic via the urine and the 
excrement. The urine and other excrements 
may change to darker red-brown or even 
greenish color [21].  Notably, a significant 
portion of the ingested Arsenic is absorbed by 
various bodily tissues and is retained over an 
extended period of time. Some of the Arsenic that enters the body is excreted out of the 
body rather rapidly but a fraction of it accumulates in various organs including the blood 
vessels in addition to the hair and the nails. The fraction of Arsenic that is retained in the 
body depends on the specific Arsenic compound that entered, the  portal that it entered 
through, i.e. ingestion or inhalation, and other components present in the food that  were 
consumed  together. While such arsenic based toxic wastes are liberated very slowly, 
nevertheless they cause physiological damage in various organ systems [22].	
A few important facts pertinent to Arsenic Poisoning: 
1. Every person is exposed daily to Arsenic because most 
drinking waters and foods contain trace amounts of arsenic. 
2. The body can tolerate small doses of Arsenic without 
noticeable immediate physiological effects. 
3. Arsenic atoms may be present in compounds in the trivalent or 
the pentavalent form. 
4. Arsenic may be connected to carbon atoms, in which case 
the compound is called ORGANIC or may be connected to 
other types of atoms, when it will be called INORGANIC. 
Inorganic arsenic compounds are in general much more toxic 
than organic compounds. 
5. Many Arsenic compounds will impart a garlic-like smell to a 
food or to the breath of the person who consumes them. 
6. Since the chemical properties of Arsenic are very similar to the 
properties of phosphorous, and because phosphorous 
compounds are critical in numerous biochemical functions in 
the body, Arsenic is toxic in all functions where biochemical 
reactions that involve phosphorous are involved.	
Overview of the human exposure to arsenic 
 
- Non-occupational human exposure to arsenic in the 
environment is primarily through the ingestion of food and 
water.  
- The daily intake of total arsenic from food and beverages 
is generally between 20 and 300 µg/day.  
- Foodstuffs such as meat, poultry, dairy products and 
cereals have higher levels of inorganic arsenic.  
- Pulmonary exposure may contribute up to approximately 10 
µg/day in a smoker and about 1 µg/day in a non-smoker, 
and more in polluted areas.  
- The concentration of metabolites of inorganic arsenic in urine 
ranges from 5 to 20 µg of arsenic/liter, but may even exceed 
1000 µg/liter. 
- In workplaces with up-to-date occupational hygiene 
practices, exposure generally does not exceed 10 µg/m3 (8-h 
time-weighted average. 	
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Recent clinical research has shown that arsenic trioxide, administered intravenously, 
could induce cancer remission in some people with refractory acute promyelocytic 
leukemia [23, 24]. Although the highly suggestive but inconclusive epidemiological 
evidences support the Arteriosclerotic lesions, ischemic heart disease and thereby 
increased mortality risk was increased among arsenic-exposed persons [25, 26]. 
Arsenic can trigger multiple abnormal electrocardiographic patterns not limited to 
ventricular tachyarrhythmia [27, 28]. While the carcinogenic and cancer therapeutic 
potentials of arsenic have widely been studied, there is a relatively smaller attention to 
arsenic induced CVDs [29].  	
 
 
Arsenic and 
Cardiovascular diseases 
Being long considered a potent 
human health hazard due to its 
neoplastic outcomes, Arsenic 
also shows increasing 
epidemiological evidence of links 
between Arsenic exposure and 
risks of CAD and CVDs. As 
mentioned earlier, Arsenic is a 
major risk factor for the endemic 
peripheral artery disease 
characterized by severe 
arteriosclerosis and subsequent 
gangrene of affected extremities, 
so-called ‘‘Blackfoot’’ disease (BFD) [30, 31]. In addition, systemic vascular disease 
have been epidemiologically linked to chronic Arsenic exposure. High mortality from 
ischemic heart disease was first reported in copper smelter workers who were exposed 
to arsenic [32]. In the United States epidemiological studies correlations between 
standard mortality ratios for cardiovascular diseases and arsenic levels in food and 
drinking water [33, 34].  In our experimental system acute exposure of inorganic arsenic 
induced tachycardia in isolated amphibian hearts similar to adrenalin that could have 
been blocked by a beta blocker (Figure 1). Ischemic heart disease and cerebral 
infarction are considered late clinical manifestations of generalized atherosclerotic 
process and ultrasound studies in the superficial carotid artery indicated a dose 
response relationship between carotid atherosclerosis and chronic exposure to arsenic 
[33, 35, 36]. In the aforementioned studies, a significant biological links have been 
observed after careful adjustment of the statistical data for major CVD risk factors, 
signifying arsenic exposure as a potential independent risk factor for atherosclerosis, 
CAD, and increased incidences of cardiovascular morbidity, mortality. 	
	
Figure 1: Arsenic induce tachycardia in isolated amphibian heart.  
Brief exposure of inorganic Arsenic (Na-Arsenate) induce tachycardia 
that could be counteracted by beta blockers in isolated amphibian heart.	
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Chronic low dose exposure to Arsenic induce endothelial dysfunction 
The endothelium, being most sensitive to systemic or micro-environmental stress, is one 
of the prime target of chronic arsenic toxicity. Naturally occurring and highly toxic 
inorganic form arsenic rapidly induces reactive oxygen species (ROS) formation and 
thereby induce proliferation response in vascular smooth muscle cells. The net effect of 
such activity is attenuation of endothelium-dependent conduit artery dilation via 
downregulation of endothelial NO synthase, events that are temporally matched to the 
accumulation of oxidants across the vessel wall.  Reduced expression of endothelial 
nitric oxide synthase (eNOS) leading to diminished bioavailability of vasodilating nitric 
oxide (NO) is a hallmark of endothelial dysfunction. 	
A number of earlier publications indicate that Arsenic imposes serious threats to 
cardiovascular health and co-morbidity. Reports of chronic arsenic exposure induced 
CVD related mortality, endothelial dysfunction, dysregulated lipid metabolism, and some 
other detailed mechanistic studies are also starting to emerge [1, 37-41]. Moreover, in a 
recent study it was shown that even habitual fish intake, although generally reflect 
healthier dietary habits with favorable effects on the endothelial function, can actually 
increase the chronic exposure levels of Arsenic and subsequent deleterious alteration in 
the arterial flow mediated dilation (FMD) – a clinical indicator of endothelial dysfunction 
[42]. Chronic low exposure to arsenic induce Cyclin D1 dependent NFkB/BCL3 
mediated pathways leading to cellular proliferation [43]. In addition, other associated 
deleterious effects of chronic Arsenic exposure includes generation and persistence of 
proactive platelet, induction of dyslipidemia and increase endothelial adhesion of 
activated monocytes initiating a pro-atherogenic condition [38, 44]. 	
Our recent studies indicate that a range of ultra-low concentrations of Arsenic (10nM – 
10µM) exposure significantly down-regulate the mRNA levels of eNOS in addition 
significantly diminished expression of Krüppel-like Factor 2 (KLF2) and Krüppel-like 
Factor 4 (KLF4)  in HUVEC (not shown), and in primary human aortic endothelial cells 
respectively. Krüppel-like factors 2 and 4 are pivotal laminar flow inducible transcription 
factors that modulate several genes critical for maintaining an antithrombotic endothelial 
surface [45, 46]. KLF2 is a key determinant of the anti-inflammatory and anti-
atherogenic vascular environment [47-49], and a potent inducer of endothelial nitric 
oxide synthase (eNOS) [50].  KLF2 blocks expression of the procoagulant Tissue Factor 
[51] and also inhibits thrombin-induced activation of endothelial cells by decreasing 
expression of the thrombin-activated protease activated receptor type 1 (PAR-1), 
conversely, TNF-α, IL-1β, and oxidative stress, repress KLF2 expression in the 
endothelial cells (EC) [52]. KLF4 is also an independent regulator of EC function, and is 
protective against atherosclerosis [53]. According to reports, Krüppel-like factors (KLFs) 
are important mediators of monocyte differentiation and activation as well.  KLF2 is a 
negative regulator of proinflammatory genes both in the ECs and monocytes and 
expression of KLF2 in monocytes is reduced following exposure to TNF-α or LPS and in 
monocytes from patients with coronary artery disease [54].  Krüppel-like factor 4 is also 
involved in myeloid cell differentiation [55] and is a critical regulator of macrophage 
polarization; in vitro exposure of mouse macrophages to LPS, proinflammatory 
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cytokines, or oxLDL, results in decreased KLF4 levels [53, 56].  Mouse macrophages 
deficient in KLF4 have enhanced foam cell formation in response to oxLDL [53]. Our 
preliminary observations shows brief exposure of inorganic Arsenic in nanomolar 
concentration induce  significant down-regulation of several other endothelial regulator 
genes including increased expression of VCAM-1, and E-selectin ( unpublished 
observations, not shown) in HUVEC (Human Umbilical Vein Endothelial Cell).	
 To determine whether the reduced 
eNOS expression in Arsenic 
exposed endothelial cells and other 
peripheral blood mononuclear cells 
(not shown), could be linked to a 
reduced expression of endothelial 
KLF4 (and KLF2: not shown), we 
examined nuclear KLF4 levels by 
immunofluorescence microscopy, 
normalizing the digitized nuclear 
KLF4 fluorescence to nuclear DNA 
(as measured by DAPI 
fluorescence).  We observed 
significantly reduced KLF4 
expression in Arsenic exposed 
primary human aortic endothelial 
cells when compared to the KLF4 
expression in untreated control cells 
(Figure 2a. ***p < 0.001).                             
Interestingly, when the nuclear 
levels of histone H3, as an internal 
control, was measured using 
identical parameters no such dose 
or time dependent effect of Arsenic 
exposure on in the endothelial cells 
was observed (Figure 2b.). We 
confer, the vascular micro-
environment during Arsenic 
exposure is pathologically modified 
characterizing a diminished 
expression of the anti-inflammatory 
and anti-atherogenic transcriptional 
regulator KLF2 and KLF4 in 
addition to significant reduction in 
eNOS production and increased expression of endothelial adhesion molecules, like 
VCAM-1 and E-selectin. Here, we provide a comprehensive set of data showing the 
effects of low dose Arsenic exposure (10µM) at different time point on cultured primary 
human aortic endothelium from descending thoracic aorta (Figure 2). 
  
Figure 2: Arsenic exposure reduce Krüppel-like Factor 4 
expression in human aortic endothelial cells in a time and dose 
dependent manner. Human primary aortic endothelial cells were 
grown in sterile chamber slides, and exposed to 10mM of Arsenic at 
the indicated time points. The cells were subsequently 
immunostained and digital images were recorded by epi-fluorescence 
microscopy (EVOSÒFL, Life Technologies) using a 100X objective 
(20X images for large scale data acquisition and analyses) for the 
detection and analysis of nuclear KLF4 (Panel a) and Histone H3 
(Panel b.) as internal control. Quantitative fluorescence intensity ratio 
(KLF4:DAPI) data of 100 cells at each time point from 3 independent 
experiments are presented to the right of each panel. The data were 
compared using a two tailed Mann Whitney test. ***p<0.001. 
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Arsenic-induced molecular and 
cellular events related to 
atherogenesis: In vitro studies 
cultured human endothelial cell 
indicate that arsenic can initiate 
oxidative damage, activation of 
transcription factors, and gene 
expression relevant to 
endothelial dysfunction and 
CVDs (Figure 3). Chronic 
exposure to Arsenic is also a 
potential risk factor for type 2 
diabetes. 
Exposure to inorganic Arsenic 
induces pre-diabetic effects by 
altering deregulating lipid 
metabolism, gluconeogenesis 
and insulin secretion in healthy 
individuals, and worsens 
glucose metabolism in 
established diabetics although 
insulin resistance might be not 
the sole reason of diabetic 
effects caused by inorganic 
Arsenic [57].	
 
Arsenic exposure, cardiovascular diseases and global HIV incidences:  
Cardiovascular abnormalities are common in HIV-infected individuals but often go 
unrecognized or untreated, which results in increased cardiovascular-related morbidity 
and mortality and reduced quality of life. Clinicians may mistakenly attribute signs of 
cardiovascular abnormalities to pulmonary or infectious causes, an error that can delay 
appropriate treatment. Despite a dramatic improvement in survival in the antiretroviral 
therapy (ART) era, there remains an increased risk of thromboembolic and 
cardiovascular co-morbidities in these treated [58-60]. The core mechanism(s) that 
contribute to this increased risk of CVD in HIV disease have not been fully elucidated, 
but may be partially related to chronic immune activation [61, 62]. Systemic indices of 
inflammation and coagulation have been linked to cardiovascular risk in HIV infection 
[63] and PET CT scans have demonstrated metabolic evidence of aortic inflammation in 
treated HIV infection [64]. 	
	
 
Figure 3: Schematic view of plausible arsenic induced oxidative 
damage and endothelial dysfunction. Arsenic interacts with G	Protein	
Coupled	 Receptors	 (GPCR) to initiate signal amplification schemes 
regulating NOX-dependent redox signaling. Downstream signaling for 
dysfunction was (partially adapted from: States JC, et al., Toxicol 
Sci. 2009.[1]). 
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Figure 4: Global Arsenic exposure (A), 
Cardiovascular/other diseases (B), HIV/AIDS 
Prevalence in 2013 (C), and the projected overlaps 
(lower panel).	
Endothelium is a highly reactive surface,  
responding to a myriad of micro-environmental 
stress-inducing factors resulting from infection 
tissue injury, and inflammation [65]. ECs serve 
as selective micro environmental barriers for the 
exchange of fluid and macromolecules from the 
vascular compartment to the tissue. In addition, 
the bidirectional relationship that follows 
between the coagulation pathways and vascular 
inflammation modulating endothelial 
homeostasis is widely recognized [66, 67].	
We showed in one of our recent reports that 
eNOS and KLF2 are significantly downregulated 
inducing endothelial dysfunction along with a 
dramatic increase in the subendothelial 
migration of CD8 T cells and inflammatory 
monocytes in the aortic endothelium of Rhesus 
macaque who are acutely infected with simian 
immunodeficiency virus (SIV)- the HIV 
homologue infecting non-human primates  [68] 
How such downregulation affects the formation 
and sustenance of the immunological synapse 
bond is of extreme importance in defining the 
immune lifeline of an affected individual. An 
immediate future extension of our present line of 
research in this field is to analyze such effects 
based on mathematical and probabilistic models 
that will also highlight the quantitative 
importance of all affecting factors.	
Chronic low dose exposure to inorganic Arsenic 
and Arsenicals, endothelial dysfunction, CVD, 
and an association of endemic HIV infections 
opens up future avenues of research into, what 
is a relatively poorly understood topic with major implications for human health. While 
the data acquisition on the world prevalence of HIV and cardiovascular diseases is 
thorough, the data on chronic exposure to Arsenic is still incomplete for most part of the 
world. But, we know a large sum of the world population, mostly unknowingly, is 
exposed to Arsenic irrespective of the socioeconomic status or geographical location of 
their country. This is a fact which generally indicate that the HIV infected population who 
are on continued anti-retroviral therapy (ART) with controlled viremia, are also exposed 
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to low, moderate or high levels of environmental Arsenic that might be an additional 
trigger in initiating their accelerated endothelial dysfunction and atherosclerotic lesions. 
Determination of the true risk of CVD in HIV and measuring the synergistic effects of 
Arsenic exposure that further complicates the pathogenesis of CVD will become 
increasingly important in the long-term management of HIV-infected patients receiving 
antiretroviral therapy.	
Arsenic Modelling and Transport	
As described above, Arsenic is now widely accepted to have a dual role as a causative 
and a curative agent primarily in non-infectious disease proliferation [69] but also as a 
secondary instigator of population infection [70]. While conventional biology is typically a 
first resort, probabilistic prediction of affectation and disease proliferation often stretch 
beyond the realms of experimental data, especially in predicting what levels of 
fluctuation of the affecting parameters could instigate a certain threshold of arsenic 
inflicted persecution. As an example, if the water arsenic toxicity factor increases by 5% 
over the next 3 years while the glutathione depletion factor decreases by 7% leading to 
an overall protein inactivation increase by 8% (considering only a few token factors) 
during the same time span, what will be the increase in arsenic afflicted atherosclerosis 
and CVD during this time? To address such questions in a non-invasive procedure, 
computer based data analysis and statistical modeling is the new genre of science in 
this interdisciplinary arena.  
Techniques from statistical mechanics, thermodynamics and nonlinear mechanics, 
together with native computer simulation, has started unearthing lots of features that 
have so far remained outside the conventional research purview. In a recent ensemble 
modeling approach, a mathematical model has been studied that predicts intracellular 
arsenic flow rates under varying mutant conditions, focusing on the toxicity mechanism 
of arsenic. This data based analyzes clearly highlight an array of important conclusions 
like a) protein based arsenic profiles have short-termed exposure while glutathione 
based arsenic compounds have longer termed ramifications; b) arsenic dynamics is 
mostly a transient mechanism that probabilistically escapes the vacuole via natural 
export mechanism, etc. While this work was studied on a yeast substrate, more 
indicative suggestions towards the protein-versus-glutathione debate have been 
advised. While this line of modeling directly assesses the microbiological origin of its 
affectation, secondary infections in the form of (Buruli) ulcerous swellings, believed to 
be arsenic inflicted, have recently been studied using data from chosen African 
countries [70]. The results from this study indicate without confirming as much the 
importance of environmental implication of arsenic disease propagation. Similar results 
were obtained a while ago by a South African modeling group who studied the optimal 
control of arsenic transmission dynamics targeting mycobacterium ulceran infection 
[71]. While the data analysis results [70] indicated the roots of the proliferation mode, 
this more recent kinetic equation based nonlinear modeling [71] traced the mitigation 
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mechanism as an optimal combination of environmental and health education together 
with water purification protocols.  
Modeling attempts at arsenic retention processes in wetland areas is another line of 
complementary research that focuses on the role of trace elements in arsenic effect 
proliferation. Analyzing a model representing arsenic propagation dynamics in 
constructed wetlands targeting a quantitative prediction of the mutual relationship 
between iron and arsenic retention efficiency increase, the model results indicate a 
maximum arsenic retention efficiency of 85-95% [72]. What all such effects ultimately 
culminate at is in the population response to exposure of chemical carcinogens at low to 
high exposure levels often leading to a mutation of a single-cell DNA, hastening a 
terminal illness.  A consummate detailing of such “carcinogenesis modeling” can be 
availed from a self-sufficient overview by Vineis, et al. [73]. Of the five models discussed 
here, only Model 4 indirectly alludes to arsenic affectation of carcinoma, another 
indication of insufficient research in this field.  
The above highlighted areas are only the tips of the proverbial iceberg. More concerted 
efforts combining complementary inter- and cross- disciplinary efforts are needed to 
tackle this problem, an approach that has taken pace off late.  
Concluding Remarks 
Studies summarized in this mini-review suggest that chronic Arsenic exposure induces 
pathophysiological events relevant to the atherogenic potential including impaired 
vascular nitric oxide homeostasis, low Krüppel-like factor 2, 4 expression, and 
enhanced expression endothelial adhesion molecule like VCAM-1. These detrimental 
changes in the endothelial microenvironment, collectively expressed as endothelial 
dysfunction are the key molecular events in the cardiovascular system which are 
surprisingly common to Arsenic exposure and in the HIV infected patients on long-term 
ART. Based on the accumulating epidemiological evidences and experimental data, we 
conclude, arsenic exposure could be considered as an important modifying factor in the 
understating and intervention strategies of atherosclerosis and related cardiovascular 
diseases in virologically controlled HIV patients on ART, at least under certain 
circumstances (including genetic background, diet, co-exposure and geographical 
location). Also, we would argue that the considerable overlap with the worldwide 
exposure of Arsenic, incidences of HIV infection positively reinforce the initiation, 
persistence, and progress of HIV infection itself and the pathogenesis of related 
cardiovascular complications. While mathematical modeling of arsenic poisoning, 
infection and its impact on carcinogenesis is a vital and newly adopted line of research, 
the sheer paucity of material in gelling together known biological observations against 
data and mathematical models clearly indicates the need for more detailed and target 
driven studies. Over the next couple of years, such cross-platform research is expected 
to hold center stage in leading the light in this field. 	
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